Cisplatin-resistant non-small cell lung cancer cells expressed high levels of hyperactivated PARP1. Cells succumbed to PARP inhibitors in vitro. PARP inhibitor slowed cisplatin-resistant tumor growth in mice. PHILADELPHIA — Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy...
Posted to
News
by
AACR News
on
Wed, Apr 3 2013
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, Cancer Research, journal, non-small cell lung cancer, NSCLC, cisplatin, PARP1, PARP inhibitor, cisplatin resistance, PAR, Dr. Guido Kroemer
Ganetespib killed ALK-driven NSCLC cell lines more effectively than crizotinib. Displayed greater antitumor activity and prolonged survival in a mouse model. Potential as a new option for treating ALK-dependent lung cancers. PHILADELPHIA — A drug that indirectly impairs the function of several...
Posted to
News
by
AACR News
on
Tue, Mar 26 2013
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, Cancer Discovery, journal, non-small cell lung cancer, anaplastic lymphoma kinase, ALK, NSCLC, ganetespib, resistance, crizotinib, Dr. David Proia
Patients with lung cancer and KRAS mutation responded well to antifolate therapy. Response linked to downregulation of KRAS expression. Downregulation may render cells more susceptible to chemotherapeutic drug. CHICAGO — Testing patients with non-small cell lung cancer for both mutations and amplifications...
Posted to
News
by
AACR News
on
Wed, Apr 4 2012
Filed under:
Filed under: Press Releases, Research, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, meeting, KRAS, non-small cell lung cancer, pemetrexed, Dr. Sarah Bacus, 2012 Annual Meeting, Annual Meeting, AACR Annual Meeting 2012, antifolate
Patients with nonprogressive disease had improved survival rates. Five-year survival rate for stage 3B/4 patients was 50 percent. CHICAGO — Long-term follow-up of a phase II clinical trial showed encouraging survival in some patients with stage 3B/4 non-small cell lung cancer treated with...
Posted to
News
by
AACR News
on
Wed, Apr 4 2012
Filed under:
Filed under: Press Releases, Research, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, meeting, Vaccine, non-small cell lung cancer, 2012 Annual Meeting, Annual Meeting, AACR Annual Meeting 2012, belagenpumatucel-L, Dr. Lyudmila Bazhenova
Nab-paclitaxel and carboplatin yielded a 41 percent response rate. Toxicity of the combination is “tolerable.” CHICAGO — A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according...
Posted to
News
by
AACR News
on
Tue, Apr 3 2012
Filed under:
Filed under: Press Releases, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, non-small cell lung cancer, NSCLC, 2012 Annual Meeting, Annual Meeting, nab-paclitaxel, AACR Annual Meeting 2012, carboplatin, Dr. Gregory A. Otterson
Novel Hsp90 inhibitor shows activity in slowing KRAS-mutant NSCLC tumor cell growth. Use with traditional chemotherapy resulted in increased cancer cell death. Phase 2b/3 trial combined with docetaxel under way. SAN DIEGO — The investigational drug ganetespib, a synthetic second-generation Hsp90...
Posted to
News
by
AACR News
on
Tue, Jan 10 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, genetics, KRAS, non-small cell lung cancer, AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, International Association for the Study of Lung Cancer, IASLC, NSCLC, Jaime Acquaviva, David A. Proia, ganetespib, clinical trials, Hsp90 inhibitor
Survival rates were “unsatisfactory” in patients with NSCLC and a KRAS mutation. “Great need” exists for new treatment combinations in this patient population. SAN DIEGO — Sorafenib was effective in patients with non-small cell lung cancer and a KRAS mutation, but...
Posted to
News
by
AACR News
on
Mon, Jan 9 2012
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, sorafenib, KRAS, non-small cell lung cancer, AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, International Association for the Study of Lung Cancer, IASLC, NSCLC, Wouter W. Mellema
Extremely sensitive methodology can analyze a DNA sample size as small as three cells. Analysis method may be able to detect mutations in CTCs from patients with NSCLC. Method could help track progress of NSCLC and guide choice of targeted therapies. SAN DIEGO — Researchers have developed...
Posted to
News
by
AACR News
on
Mon, Jan 9 2012
Filed under:
Filed under: Press Releases, Research, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, non-small cell lung cancer, AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer, International Association for the Study of Lung Cancer, IASLC, circulating tumor cells, CTC, Heidi S. Erickson
Aggressive lung cancers harboring KRAS mutations are sensitive to antifolates. Antifolates decrease KRAS gene expression. Large clinical trials needed to investigate antifolate effects in cancers with respect to driving mutations. SAN FRANCISCO — Patients with non-small cell lung cancer who have...
Posted to
News
by
AACR News
on
Sun, Nov 13 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Conference, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, mutations, meeting, National Cancer Institute, NCI, KRAS, non-small cell lung cancer, Molecular Targets, AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, Cancer Therapeutics, EORTC, European Organisation for Research and Treatment of Cancer, pemetrexed, antifolates, methotrexate, Dr. Sarah Bacus
Therapy extended median survival to 6.4 months. Two patients are alive four years after start of epigenetic treatment. AACR will host teleconference on Nov. 9, 2011, at 11:00 a.m. ET. PHILADELPHIA — Patients with recurrent metastatic non-small cell lung cancer have a morbid prognosis, but a new...
Posted to
News
by
AACR News
on
Wed, Nov 9 2011
Filed under:
Filed under: Press Releases, Research, Treatment, Cancer, teleconference, Media Materials, AACR, lung cancer, American Association for Cancer Research, Cancer Discovery, award, Stand Up To Cancer, SU2C, journal, press conference, non-small cell lung cancer, Metastatic, entinostat, epigenetic therapy, azacitidine
CONFERENCE TO HIGHLIGHT ADVANCES IN CANCER DRUG DEVELOPMENT SAN FRANCISCO, CALIF., NOV. 12-16, 2011 What: The AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics will be held from Nov. 12-16, 2011, at the Moscone Center West in San Francisco. This unique conference combines...
Posted to
News
by
AACR News
on
Wed, Oct 5 2011
Filed under:
Filed under: Uncategorized, San Francisco, Treatment, Conference, melanoma, Cancer, Media Materials, AACR, lung cancer, American Association for Cancer Research, chemotherapy, Media Alerts, meeting, skin cancer, colon cancer, Molecular Targets and Cancer Therapeutics, non-small cell lung cancer, angiogenesis, squamous cell carcinoma, cancer drug development